Actively Recruiting
Phase 2 Study Evaluating the Safety and Efficacy of TYRA-300 in Adults With FGFR3 Altered Low Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer
Led by Tyra Biosciences, Inc · Updated on 2026-10-27
90
Participants Needed
48
Research Sites
30 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the efficacy and safety of TYRA-300 in adults with FGFR3 altered low grade, intermediate risk non-muscle invasive bladder cancer NMIBC. This phase 2, multicenter, open-label study focuses on patients who have specific genetic alterations in the FGFR3 gene and have a confirmed low-grade NMIBC tumor. The purpose is to better understand how this oral drug works in this specific group of bladder cancer patients. Participants will receive one of three self-administered daily doses of the study drug TYRA-300 as oral tablets 50 mg, 60 mg, or 70 mg. The study is randomized and parallel in design, with all participants receiving the active drug in different dose cohorts. The drug is taken daily and treatment effects will be assessed over time, with follow-up lasting up to 24 months in some cases. During the study, participants will undergo regular assessments to monitor the drugs effects and safety, including evaluations of tumor response and recurrence. Key measures include the rate of complete response at 3 months, overall response rates up to 24 months, and the duration of response. Safety will be monitored through adverse event tracking. Participants will be followed for up to two years to assess longer-term outcomes and any side effects associated with TYRA-300.
CONDITIONS
Brief Title
Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer
Research Team
G
Gina Risdall
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here